Guillain-Barre Syndrome- Pipeline Insight, 2023

Guillain-Barre Syndrome- Pipeline Insight, 2023

DelveInsight’s, “Guillain-Barre Syndrome- Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Guillain-Barre Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Guillain-Barre Syndrome: Understanding

Guillain-Barre Syndrome: Overview

Guillain-Barré Syndrome (GBS) is a rare neurological disorder in which your immune system mistakenly attacks part of the peripheral nervous system—the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with brief weakness to nearly devastating paralysis, leaving you unable to breathe independently. Fortunately, most people eventually recover from even the most severe cases of GBS. After recovery, some people will continue to have some degree of weakness.

GBS can increase in intensity over a period of hours, days, or weeks until certain muscles cannot be used at all, and, when severe, the person is almost totally paralyzed. In these cases, the disorder is life-threatening—potentially interfering with breathing and, at times, with blood pressure or heart rate.

It is an inflammatory disease of the PNS and is the most common cause of acute flaccid paralysis, with an annual global incidence of approximately 1–2 per 100,000 person-years. GBS occurs more frequently in males than in females, and the incidence increases with age, although all age groups can be affected. Patients with GBS typically present with weakness and sensory signs in the legs that progress to the arms and cranial muscles, although the clinical presentation of the disease is heterogeneous and several distinct clinical variants exist. The diagnosis of GBS is based on the patient’s history and neurological, electrophysiological, and cerebrospinal fluid (CSF) examinations.

GBS is thought to be caused by an aberrant immune response to infections that results in damage to peripheral nerves, although the pathogenesis is not fully understood. In a subgroup of patients with GBS, serum antibodies are found against gangliosides, which reside at high densities in the axolemma and other components of the peripheral nerves. Complement activation, infiltration of macrophages, and oedema are typical characteristics of affected peripheral nerves and nerve roots in patients with GBS.

Guidance for the treatment and care of patients with GBS is needed because disease progression can vary greatly between patients, which complicates an entirely prescriptive approach to management. Additionally, treatment options are limited and costly, and many patients experience residual disability and complaints that can be difficult to manage.

""Guillain-Barre Syndrome- Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Guillain-Barre Syndrome pipeline landscape is provided which includes the disease overview and Guillain-Barre Syndrome treatment guidelines. The assessment part of the report embraces, in depth Guillain-Barre Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Guillain-Barre Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Guillain-Barre Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Guillain-Barre Syndrome.

Guillain-Barre Syndrome Emerging Drugs Chapters

This segment of the Guillain-Barre Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Guillain-Barre Syndrome Emerging Drugs

Eculizumab: Alexion Pharmaceuticals

Eculizumab is a humanized monoclonal antibody of murine anti-human C5 antibody that specifically binds to the final activation complement component C5 and inhibits MAC formation by suppressing the cleavage reaction of C5 into C5a and C5b. The efficacy of Eculizumab against GBS has been shown in a model of axonal GBS. At present, there are no animal models of demyelinating GBS. However, autopsy studies have shown that C3d and C5b-9 (MAC) are deposited on the Schwan cells, and therefore Eculizumab can also be effective for demyelinating GBS.

Efgartigimod Alfa-Fcab: argenx

Efgartigimod Alfa-Fcab (Efgartigimod) is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. Currently, the drug is in Phase II stage of its clinical trial evaluation for the treatment of Guillain-Barre Syndrome.

CRES-101: Bioasis Technologies, Inc.

CRES-101 is a myelin protein stimulant. EGF1-482 (alternatively designated CRES101) has demonstrated the ability to stimulate myelination and downregulate neuroinflammation, offering potential benefits in the clinical data to patients with Guillain-Barre Syndrome. Currently, the drug is being developed by Bioasis Technologies and is in the Phase I stage.

Further product details are provided in the report……..

Guillain-Barre Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Guillain-Barre Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Guillain-Barre Syndrome

There are approx. 8+ key companies which are developing the therapies for Guillain-Barre Syndrome. The companies which have their Guillain-Barre Syndrome drug candidates in the most advanced stage, i.e. phase III include, Alexion Pharmaceuticals.

Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Guillain-Barre Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Guillain-Barre Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Guillain-Barre Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Guillain-Barre Syndrome drugs.

Guillain-Barre Syndrome Report Insights

Guillain-Barre Syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Guillain-Barre Syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Guillain-Barre Syndrome drugs?

How many Guillain-Barre Syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Guillain-Barre Syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Guillain-Barre Syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Guillain-Barre Syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Alexion Pharmaceuticals

Annexon

Argenx

Hansa Biopharma

Bioasis Technologies

Key Products

Eculizumab

ANX005

Efgartigimod Alfa-Fcab

Imlifidase

CRES-101